InvestorsHub Logo
Followers 42
Posts 4139
Boards Moderated 0
Alias Born 01/04/2017

Re: CTMedic post# 149159

Sunday, 02/28/2021 7:59:29 AM

Sunday, February 28, 2021 7:59:29 AM

Post# of 233220
From 2-27-21 paper on RLFTF product Aviptadil:

At 28 days, a Aviptadil patients treated with HFNC were 35% - 46% more likely to recover, return home, and survive to 28 days compared to placebo-treated patients, with a trend level of significance. Aviptadil patients additionally demonstrated a highly statistically significant and clinically dramatic ten day reduction in hospitalization time. Should similar findings be observed at 60 days, Emergency Use Authorization will be sought.

SSRN
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3794262

I believe the 60 day requirement is from FDA...
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News